Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer

doi:10.1002/cai2.10

Cancer Innovation 2022, 1(1): 25-54 https://doi.org/10.1002/cai2.10

Clinical Guideline |

Open Access | Issue | Published: 21 June 2022

Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer

Keywords:

breast cancer, PI3K/AKT/mTOR inhibitors

Cite this article:

Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer. Cancer Innovation, 2022, 1(1): 25-54. https://doi.org/10.1002/cai2.10

Download citation

EndNote(RIS)

BibTeX

955

Views

Downloads

Citations

Crossref

N/A

WoS

Scopus

N/A

CSCD

Abstract Full text About this article

Abstract

Phosphoinositide 3‐kinase (PI3K)/protein kinase B (PKB or AKT)/mammalian target of rapamycin (mTOR) signaling pathway (PAM pathway) plays an important role in the development of breast cancer and are closely associated with the resistance to endocrine therapy in advanced breast cancer. Therefore, anticancer treatment targeting key molecules in this signaling pathway has become a research hotspot in recent years. Randomized clinical trials have demonstrated that PI3K/AKT/mTOR inhibitors bring significant clinical benefit to patients with advanced breast cancer, especially to those with hormone receptor (HR)‐positive, human epidermal growth factor receptor (HER) 2‐negative advanced breast cancer. Alpelisib, a PI3K inhibitor, and everolimus, an mTOR inhibitor, have been approved by FDA. Based on their high efficacy and relatively good safety profile, an expanded indication of everolimus in breast cancer has been approved by National Medical Products Administration (NMPA). Alpelisib is expected to be approved in China in the near future. The members of the consensus expert panel reached this consensus to comprehensively define the role of PI3K/AKT/mTOR signaling pathway in breast cancer, efficacy and clinical applications of PI3K/AKT/mTOR inhibitors, management of adverse reactions, and PIK3CA mutation detection, to promote the understanding of PI3K/AKT/mTOR inhibitors for Chinese oncologists, improve clinical decision‐making, and prolong the survival of target patient population.

Full text

Abstract

Full text

Outline

About this article

Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer

Abstract

Keywords: breast cancer, PI3K/AKT/mTOR inhibitors

References(100)

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

DOI Google Scholar

Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021;134(7):783–91.

DOI Google Scholar

Harbeck N, Penault‐Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Primers. 2019;5(1):66.

DOI Google Scholar

Lim E, Metzger‐Filho O, Winer EP. The natural history of hormone receptor‐positive breast cancer. Oncology (Williston Park). 2012;26(8):688–94.

Google Scholar

Dong C, Wu J, Chen Y, Nie J, Chen C. Activation of PI3K/AKT/mTOR pathway causes drug resistance in breast cancer. Front Pharmacol. 2021;12:628690.

DOI Google Scholar

Nunnery SE, Mayer IA. Targeting the PI3K/AKT/mTOR pathway in hormone‐positive breast cancer. Drugs. 2020;80(16):1685–97.

DOI Google Scholar

Ciruelos Gil EM. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor‐positive breast cancer. Cancer Treat Rev. 2014;40(7):862–71.

DOI Google Scholar

Burris HA 3rd. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol. 2013;71(4):829–42.

DOI Google Scholar

Sharma VR, Gupta GK, Sharma AK, Batra N, Sharma DK, Joshi A, et al. PI3K/AKT/mTOR intracellular pathway and breast cancer: factors, mechanism and regulation. CurrPharmDes. 2017;23(11):1633–38.

DOI Google Scholar

Dienstmann R, Rodon J, Serra V, et al. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther. 2014;13(5):1021–31.

DOI Google Scholar

Brufsky AM, Dickler MN. Estrogen receptor‐positive breast cancer: exploiting signaling pathways implicated in endocrine resistance. Oncologist. 2018;23(5):528–39.

DOI Google Scholar

O'Brien NA, McDermott MSJ, Conklin D, et al. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6‐based therapies in preclinical models of hormone receptor‐positive breast cancer. Breast Cancer Res. 2020;22(1):89.

DOI Google Scholar

Li H, Prever L, Hirsch E, Gulluni F. Targeting PI3K/AKT/mTOR signaling pathway in breast cancer. Cancers (Basel). 2021;13(14):3517.

DOI Google Scholar

Novartis Pharmaceuticals Corporation. Highlights of Prescribing Information, PIQRAY® (Alpelisib) tablets, for oral use, Initial U.S. [EB/OL]. (2019‐05) [2022‐05‐10]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf

DOI

Jia M, Liao N, Chen B, Zhang G, Wang Y, Li X, et al. PIK3CA somatic alterations in invasive breast cancers: different spectrum from Caucasians to Chinese detected by next generation sequencing. Breast Cancer. 2021;28(3):644–52.

DOI Google Scholar

Novartis Pharmaceuticals Corporation. Highlights of Prescribing Information, AFINITOR® (everolimus) tablets for oral administration, AFINITOR® DISPERZ (everolimus tablets for oral suspension), Initial U.S. [EB/OL]. (2014‐07) [2022‐05‐10]. https://www.novartis.us/sites/www.novartis.us/files/afinitor.pdf?irmasrc=ONCWB0043%26source=01030.pdf.

DOI

Yardley DA, Noguchi S, Pritchard KI, Burris HA, Baselga J, Gnant M, et al. Everolimus plus exemestane in postmenopausal patients with HR (+) breast cancer: BOLERO‐2 final progression‐free survival analysis. Adv Ther. 2013;30(10):870–84.

DOI Google Scholar

Kornblum N, Zhao F, Manola J, Klein P, Ramaswamy B, Brufsky A, et al. Randomized phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative metastatic breast cancer resistant to aromatase inhibitor therapy: results of PrE0102. J Clin Oncol. 2018;36(16):1556–63.

DOI Google Scholar

Shao Z, Cai L, Wang S, Hu X, Shen K, Wang H, et al. 2021. BOLERO‐5: a phase II study of everolimus and exemestance combination in Chinese postmenopausal women with ER+/HER2‐ advanced breast cancer. ESMO POSTER 238P.

Royce M, Bachelot T, Villanueva C, Özgüroglu M, Azevedo SJ, Cruz FM, et al. Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor‐positive, human epidermal growth factor receptor 2‐negative advanced breast cancer: a clinical trial. JAMA Oncol. 2018;4(7):977–84.

DOI Google Scholar

Fan Y, Sun T, Shao Z, Zhang Q, Ouyang Q, Tong Z, et al. Effectiveness of adding everolimus to the first‐line treatment of advanced breast cancer in premenopausal women who experienced disease progression while receiving selective estrogen receptor modulators: a phase 2 randomized clinical trial. JAMA Oncol. 2021;7(10):e213428.

DOI Google Scholar

Li Y, Li W, Gong C, Zheng Y, Ouyang Q, Xie N, et al. A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbocicli/HER2‐ metastatic breast cancer. Ther Adv Med Oncol. 2021;13:17588359211022890.

DOI Google Scholar

Cidado J, Park BH. Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy. J Mammary Gland Biol Neoplasia. 2012;17(3–4):205–16.

DOI Google Scholar

McKenna M, McGarrigle S, Pidgeon GP. The next generation of PI3K‐Akt‐mTOR pathway inhibitors in breast cancer cohorts. Biochim Biophys Acta, Rev Cancer. 2018;1870(2):185–97.

DOI Google Scholar

Miricescu D, Totan A, Stanescu‐Spinu II, Badoiu SC, Stefani C, Greabu M. PI3K/AKT/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects. Int J Mol Sci. 2020;22(1):173.

DOI Google Scholar

Lee JJ, Loh K, Yap YS. PI3K/Akt/mTOR inhibitors in breast cancer. Cancer Biol Med. 2015;12(4):342–54.

DOI Google Scholar

Presti D, Quaquarini E. The PI3K/AKT/mTOR and CDK4/6 pathways in endocrine resistant HR+/HER2‐ metastatic breast cancer: biological mechanisms and new treatments. Cancers (Basel). 2019;11(9):1242.

DOI Google Scholar

Wilks ST. Potential of overcoming resistance to HER2‐targeted therapies through the PI3K/Akt/mTOR pathway. Breast. 2015;24(5):548–55.

DOI Google Scholar

Gao C, Yuan X, Jiang Z, Gan D, Ding L, Sun Y, et al. Regulation of AKT phosphorylation by GSK3β and PTEN to control chemoresistance in breast cancer. Breast Cancer Res Treat. 2019;176(2):291–301.

DOI Google Scholar

André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. alpelisib for PIK3CA‐mutated, hormone receptor‐positive advanced breast cancer. N Engl J Med. 2019;380(20):1929–40.

DOI Google Scholar

Juric D, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib (ALP)+fulvestrant (FUL) for advanced breast cancer (ABC): phase 3 SOLAR‐1 trial results. 2018 SABCS. Abstract GS3‐08 (oral).

André F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA, et al. Alpelisib plus fulvestrant for PIK3CA‐mutated, hormone receptor‐positive, human epidermal growth factor receptor‐2‐negative advanced breast cancer: final overall survival results from SOLAR‐1. Ann Oncol. 2021;32(2):208–17.

DOI Google Scholar

Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz‐Borrego M, Neven P, et al. Alpelisib plus fulvestrant in PIK3CA‐mutated, hormone receptor‐positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open‐label, non‐comparative study. Lancet Oncol. 2021;22(4):489–98.

DOI Google Scholar

Rugo HS, Lerebours F, Juric D, Turner N, Chia S, Drullinsky P, et al. Alpelisib + letrozole in patients with PIK3CA‐mutated, hormone receptor‐positive (HR+), human epidermal growth factor receptor 2‐negative (HER2–) advanced breast cancer (ABC) previously treated with a cyclin‐dependent kinase 4/6 inhibitor (CDK4/6i) + fulvestrant: BYLieve study results. 2020 SABCS. Abstract PD2‐07 (poster).

Chia S, Ruiz‐Borrego M, Drullinsky P, Juric D, Bachelot T, Rugo HS, et al. Impact of duration of prior cyclin‐dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor‐2–negative (HER2–), PIK3CA‐mutated advanced breast cancer (ABC) from BYLieve. ASCO. Abstract 1060 (poster). 2021.

Rugo HS, Neven P, Saffie I, Park YH, De Laurentiis M, Lerebours F, et al. Alpelisib + fulvestrant in patients with PIK3CA‐mutated, HR+, HER2– advanced breast cancer (ABC) who received chemotherapy or endocrine therapy (ET) as immediate prior treatment: BYLieve cohort c primary results and exploratory biomarker analyses. 2021. SABCS. Poster PD13‐05.

Lu YS, Lee KS, Chao TY, Tseng LM, Chitapanarux I, Chen SC, et al. A phase ib study of alpelisib or buparlisib combined with tamoxifen plus goserelin in premenopausal women with HR‐positive HER2‐negative advanced breast cancer. Clin Cancer Res. 2021;27(2):408–17.

DOI Google Scholar

National Comprehensive Cancer Network. NCCN clinical practical guidelines in oncology breast cancer. Version 2. [EB/OL]. (2021‐12‐20) [2022‐05‐10]. https://www.nccn.org/.

Advanced Breast Cancer Sixth International Consensus Conference. 4‐6 November 2021.

Breast Cancer Professional Committee of Chinese Anti‐Cancer Society. Chinese Association of Cancer Diagnosis and Treatment guidelines for Breast cancer (2021 edition). Chin J Cancer. 2021;31(10):954–1040.

DOI Google Scholar

Bedard PL, Jhaveri K, Cervantes A, Gambardella V, Hamilton E, Italiano A, et al. A phase I/Ib study evaluating GDC‐0077 + palbociclib (palbo) + fulvestrant in patients (pts) with PIK3CA‐mutant (mut), hormone receptor‐positive/HER2‐negative metastatic breast cancer (HR+/HER2‐ mBC). 2020. SABCS. Poster PD1‐2.

Jhaveri K, Juric D, Varga A, Turner N, Schmid P, Saura C, et al. Preliminary correlative analysis of clinical outcomes with PIK3CA mutation (mut) status from a phase I/Ib study of GDC‐0077 in patients (pts) with hormone receptor‐positive/HER2‐negative metastatic breast cancer (HR+/HER2‐mBC). 2020. SABCS. Poster PS5‐12.

Juric D, Bedard PL, Cervantes A, Gambardella V, Oliveira M, Saura C, et al. A phase I/Ib study of inavolisib (GDC‐0077) in combination with fulvestrant in patients (pts) with PIK3CA‐mutated hormone receptor‐positive/HER2‐negative (HR+/HER2–) metastatic breast cancer. 2021 SABCS. Poster P5‐17‐05.

Dent R, Kim SB, Oliveira M, Barrios C, O'Shaughnessy J, Isakoff SJ, et al. Double‐blind placebo (PBO)‐controlled randomized phase III trial evaluating first‐line ipatasertib (IPAT) combined with paclitaxel (PAC) for PIK3CA/AKT1/PTEN‐altered locally advanced unresectable or metastatic triple‐negative breast cancer (aTNBC): primary results from IPATunity130 Cohort A. SABCS 2020. GS3‐04.

Jones RH, Casbard A, Carucci M, Cox C, Butler R, Alchami F, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor‐positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2020;21(3):345–57.

DOI Google Scholar

Smyth LM, Tamura K, Oliveira M, Ciruelos EM, Mayer IA, Sablin MP, et al. Capivasertib, an AKT kinase inhibitor, as monotherapy or in combination with fulvestrant in patients with AKT1E17K‐mutant, ER‐positive metastatic breast cancer. Clin Cancer Res. 2020;26(15):3947–57.

DOI Google Scholar

Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, et al. Everolimus plus exemestane for hormone‐receptor‐positive, human epidermal growth factor receptor‐2‐negative advanced breast cancer: overall survival results from BOLERO‐2†. Ann Oncol. 2014;25(12):2357–62.

DOI Google Scholar

Bachelot T, Bourgier C, Cropet C, Ray‐Coquard I, Ferrero JM, Freyer G, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. 2012;30(22):2718–24.

DOI Google Scholar

Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak A, Yardley DA, et al. Phase I/II trial of exemestane, ribociclib, and everolimus in women with HR+/HER2‐ advanced breast cancer after progression on CDK4/6 inhibitors (TRINITI‐1). Clin Cancer Res. 2021;27(15):4177–85.

DOI Google Scholar

Xi J, Oza A, Thomas S, Ademuyiwa F, Weilbaecher K, Suresh R, et al. Retrospective analysis of treatment patterns and effectiveness of palbociclib and subsequent regimens in metastatic breast cancer. J Natl Compr Canc Netw. 2019;17(2):141–7.

DOI Google Scholar

Yi Z, Liu B, Sun X, Rong G, Wang W, Li H, et al. Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor‐positive breast cancer and the exploration of biomarkers. Breast. 2020;52:17–22.

DOI Google Scholar

Novartis Pharmaceuticals Corporation. Highlights of Prescribing Information, PIQRAY® (Alpelisib) tablets, for oral use, Initial HK. [EB/OL]. (2020‐11‐05) [2022‐05‐10].

DOI

Kirchner GI, Meier‐Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004;43(2):83–95.

DOI Google Scholar

Huang X, Liu G, Guo J, Su Z. The PI3K/AKT pathway in obesity and type 2 diabetes. Int J Biol Sci. 2018;14(11):1483–96.

DOI Google Scholar

Goldman JW, Mendenhall MA, Rettinger SR. Hyperglycemia associated with targeted oncologic treatment: mechanisms and management. Oncologist. 2016;21(11):1326–36.

DOI Google Scholar

Goncalves MD, Hopkins BD, Cantley LC. Phosphatidylinositol 3‐kinase, growth disorders, and cancer. N Engl J Med. 2018;379(21):2052–62.

DOI Google Scholar

Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. Cell. 2017;170(4):605–35.

DOI Google Scholar

Rugo HS, André F, Yamashita T, Cerda H, Toledano I, Stemmer SM, et al. Time course and management of key adverse events during the randomized phase III SOLAR‐1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR‐positive advanced breast cancer. Ann Oncol. 2020;31(8):1001–10.

DOI Google Scholar

Rugo HS, Lacouture ME, Goncalves MD, Masharani U, Aapro MS, O'Shaughnessy JA. A multidisciplinary approach to optimizing care of patients treated with alpelisib. Breast. 2022;61:156–67.

DOI Google Scholar

Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone‐receptor‐positive advanced breast cancer. N Engl J Med. 2012;366(6):520–9.

DOI Google Scholar

Gong C, Xiao Q, Li Y, Gu Y, Zhang J, Wang L, et al. Everolimus‐related pneumonitis in patients with metastatic breast cancer: incidence, radiographic patterns, and relevance to clinical outcome. Oncologist. 2021;26(4):e580–87.

DOI Google Scholar

Rugo HS, Pritchard KI, Gnant M, Noguchi S, Piccart M, Hortobagyi G, et al. Incidence and time course of everolimus‐related adverse events in postmenopausal women with hormone receptor‐positive advanced breast cancer: insights from BOLERO‐2. Ann Oncol. 2014;25(4):808–15.

DOI Google Scholar

Seiler S, Kosse J, Loibl S, Jackisch C. Adverse event management of oral mucositis in patients with breast cancer. Breast Care (Basel). 2014;9(4):232–7.

DOI Google Scholar

Rugo HS, Seneviratne L, Beck JT, Glaspy JA, Peguero JA, Pluard TJ, et al. Prevention of everolimus‐related stomatitis in women with hormone receptor‐positive, HER2‐negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single‐arm, phase 2 trial. Lancet Oncol. 2017;18(5):654–62.

DOI Google Scholar

Aapro M, Andre F, Blackwell K, Calvo E, Jahanzeb M, Papazisis K, et al. Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. Ann Oncol. 2014;25(4):763–73.

DOI Google Scholar

Duran I, Goebell PJ, Papazisis K, Ravaud A, Weichhart T, Rodriguez‐Portal JA, et al. Drug‐induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms. Expert Opin Drug Saf. 2014;13(3):361–72.

DOI Google Scholar

Working Committee of Respiratory Pathology, Branch of Respiratory Physicians, Chinese Medical Association. Chinese expert consensus on pathologic diagnosis of common interstitial pneumonia (draft). China J Tuberculosis Respiratory. 2018;41(3):186–90.

Google Scholar

Everolimus Clinical Safety Management Expert Panel. Expert opinion on clinical safety management of everolimus. China New Drug J. 2014;(22):2694–700.

Peddi PF, Shatsky RA, Hurvitz SA. Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer. Cancer Treat Rev. 2014;40(2):320–6.

DOI Google Scholar

Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304(5670):554.

DOI Google Scholar

Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010;28(6):1075–83.

DOI Google Scholar

Mukohara T. PI3K mutations in breast cancer: prognostic and therapeutic implications. Breast Cancer. 2015;7:111–23.

DOI Google Scholar

Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, et al. Breast cancer‐associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 2005;65(23):10992–1000.

DOI Google Scholar

Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther. 2004;3(8):772–5.

DOI Google Scholar

Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004;64(21):7678–81.

DOI Google Scholar

Levine DA, Bogomolniy F, Yee CJ, Lash A, Barakat RR, Borgen PI, et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res. 2005;11(8):2875–8.

DOI Google Scholar

Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene. 2005;24(8):1477–80.

DOI Google Scholar

Chen L, Yang L, Yao L, Kuang XY, Zuo WJ, Li S, et al. Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients. Nat Commun. 2018;9(1):1357.

DOI Google Scholar

Martínez‐Sáez O, Chic N, Pascual T, Adamo B, Vidal M, González‐Farré B, et al. Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast Cancer Res. 2020;22(1):45.

DOI Google Scholar

Yi Z, Ma F, Li C, Chen R, Yuan L, Sun X, et al. Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis. Sci Rep. 2017;7(1):5995.

DOI Google Scholar

Deng L, Zhu X, Sun Y, Wang J, Zhong X, Li J, et al. Prevalence and prognostic role of PIK3CA/AKT1 mutations in chinese breast cancer patients. Cancer Res Treat. 2019;51(1):128–40.

DOI Google Scholar

Burstein HJ, Somerfield MR, Barton DL, Dorris A, Fallowfield LJ, Jain D, et al. Endocrine treatment and targeted therapy for hormone receptor‐positive, human epidermal growth factor receptor 2‐negative metastatic breast cancer: ASCO Guideline Update. J Clin Oncol. 2021;39(35):3959–77.

DOI Google Scholar

Cardoso F, Paluch‐Shimon S, Senkus E, Curigliano G, Aapro MS, André F, et al. 5th ESO‐ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623–49.

DOI Google Scholar

Ciruelos EM, Loibl S, Mayer IA, Campone M, Rugo HS, Arnedos M, et al. Clinical outcome of alpelisib plus fulvestrant in hormone receptor‐positive, human epidermal growth factor receptor 2‐negative advanced breast cancer with PIK3CA alterations detected in plasma ctDNA by next‐generation sequencing: biomarker analysis from the solar‐1 study. 2020 SABCS. PD2‐06.

Rugo H, Mayer I, Conte P, Loibl S, Campone M, Juric D, et al. Prevalence of PIK3CAmutations in patients with hormone receptor‐positive, human epidermal growth factor‐2‐negative advanced breast cancer from the SOLAR‐1 trial. 2019. AACR. Abstract CT142.

QIAGEN GmbH. therascreen® PIK3CA RGQ PCR Kit Instructions for Use (Handbook). [EB/OL]. (2019‐05) [2022‐05‐10]. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P190001.

U.S. FOOD&DRUG ADMINISTRATION. Premarket Approval (PMA), FoundationOne Liquid CDx (F1 Liquid CDx). https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P200006. [EB/OL].

Rugo HS, Raskina K, Schrock AB, Israel MA, Sokol E, Sivakumar S, et al. Real‐world (rw) clinical outcomes on alpelisib (ALP) in patients (pts) with breast cancer (BC) and PIK3CA mutations (PIK3CAm). 2021. ASCO. Abstract 1068.

Juric D, Andre F, Singer CF, Sohn J, Campone M, Loibl S, et al. Clinical outcomes of alpelisib in hormone receptor‐positive, human epidermal growth factor receptor‐2‐negative advanced breast cancer by next‐generation sequencing‐detected PIK3CA alteration status and phosphatase and tensin homolog loss: biomarker analysis from the SOLAR‐1 study. 2019.

My Cancer Genome®, GENETICALLY INFORMED CANCER MEDICINE. Types of Molecular Tumor Testing. [EB/OL]. (2014‐06) [2022‐05‐10]. https://www.mycancergenome.org/content/page/molecular-testing

Jain S, Shah AN, Santa‐Maria CA, Siziopikou K, Rademaker A, Helenowski I, et al. Phase I study of alpelisib (BYL‐719) and trastuzumab emtansine (T‐DM1) in HER2‐positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy. Breast Cancer Res Treat. 2018;171(2):371–81.

DOI Google Scholar

Saura C, Hlauschek D, Oliveira M, Zardavas D, Jallitsch‐Halper A, de la Peña L, et al. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor‐positive, HER2‐negative, early‐stage breast cancer (LORELEI): a multicentre, randomised, double‐blind, placebo‐controlled, phase 2 trial. Lancet Oncol. 2019;20(9):1226–38.

DOI Google Scholar

Infinity Pharmaceuticals presents updated data from phase 2 MARIO‐275 trial in urothelial cancer (UC) and phase 2 MARIO‐3 trial in triple negative breast cancer (TNBC). News release. Infinity Pharmaceuticals. 2021 July 27 [cited 2021 July 28]. Available from: https://investors.infi.com/node/17446

García‐Sáenz JÁ, Martínez‐Jáñez N, Cubedo R, Jerez Y, Lahuerta A, González‐Santiago S, et al. Sapanisertib plus fulvestrant in postmenopausal women with estrogen receptor‐positive/HER2‐negative advanced breast cancer after progression on aromatase inhibitor. Clin Cancer Res. 2022;28(6):1107–16.

DOI Google Scholar

Schmid P, Zaiss M, Harper‐Wynne C, Ferreira M, Dubey S, Chan S, et al. Fulvestrant plus vistusertib vs fulvestrant plus everolimus vs fulvestrant alone for women with hormone receptor‐positive metastatic breast cancer: the MANTA phase 2 randomized clinical trial. JAMA Oncol. 2019;5(11):1556–64.

DOI Google Scholar

Study of LEE011, BYL719 and letrozole in advanced ER+breast cancer. [EB/OL]. (2014‐05‐20) [2022‐05‐10]. https://www.mycancergenome.org/content/clinical_trials/NCT01872260

Sharma P, Farooki A, Fasching PA, Klauss G, Wong C, André F, et al. EPIK‐B3: a phase III, randomised, double‐blind (DB), placebo (PBO)‐controlled study of alpelisib (ALP) + nab‐paclitaxel (nab‐PTX) in advanced triple‐negative breast cancer (TNBC) with either PIK3CA mutation or phosphatase and tensin homolog (PTEN) loss without PIK3CA mutation. 2020 ESMO Poster 349 TiP.

Hurvitz SA, Chia SKL, Ciruelos EM, Hu X, Im S, Janni M, et al. EPIK‐B2: a phase III study of alpelisib (ALP) as maintenance therapy with trastuzumab (T) and pertuzumab (P) in patients (pts) with PIK3CA‐mutated (mut) human epidermal growth factor receptor‐2–positive (HER2+) advanced breast cancer (ABC). 2020. ESMO Poster 352 TiP.

DOI

Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, et al. Combination of everolimus with trastuzumab plus paclitaxel as first‐line treatment for patients with HER2‐positive advanced breast cancer (BOLERO‐1): a phase 3, randomised, double‐blind, multicentre trial. Lancet Oncol. 2015;16(7):816–29.

DOI Google Scholar

André F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, et al. Everolimus for women with trastuzumab‐resistant, HER2‐positive, advanced breast cancer (BOLERO‐3): a randomised, double‐blind, placebo‐controlled phase 3 trial. Lancet Oncol. 2014;15(6):580–91.

DOI Google Scholar

About this article

Publication history

Acknowledgements

Rights and permissions

Publication history

Received: 05 April 2022

Accepted: 05 May 2022

Published: 21 June 2022

Issue date: June 2022

Copyright

Acknowledgements

None.

Rights and permissions

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.